The EU Commission clears a merger subject to remedies in the pharmaceutical market (GlaxoSmithKline / Pfizer Consumer Health Business)

Mergers: Commission approves GlaxoSmithKline's acquisition of Pfizer's Consumer Health Business, subject to conditions* Commission has approved, under the EU Merger Regulation, the acquisition of Pfizer's Consumer Health Business by GlaxoSmithKline. The decision is conditional upon the global divestment of Pfizer's topical pain management business carried out under the ThermaCare brand. GlaxoSmithKline (“GSK”) and Pfizer's Consumer Health Business are both manufacturers and suppliers of a variety of consumer healthcare pharmaceuticals, which are typically available to patients without a prescription from a doctor and generally referred to as “over-the-counter” (“OTC”) pharmaceutical products. Both companies are active in the European Economic Area (“EEA”) in a number of OTC product

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Commission, The EU Commission clears a merger subject to remedies in the pharmaceutical market (GlaxoSmithKline / Pfizer Consumer Health Business), 10 July 2019, e-Competitions Bulletin July 2019, Art. N° 91175

Visites 215

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues